Ascentage Pharma Group International (FRA:36X) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:36X Ascentage Pharma Group International FRA:36X
68 GF Score
Price €3.80
GF Value €4.49
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Ascentage Pharma Group International's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

FRA:36X vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Ascentage Pharma Group International's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Margin of Safety % (DCF Dividends Based) falls into.


FRA:36X
68GF Score
Ascentage Pharma Group International FRA:36X
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ascentage Pharma Group International (FRA:36X) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of €3.80 is trading 15.4% below its estimated GF Value™ of €4.49.

Key valuation signals for FRA:36X:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €4.49 vs. price of €3.80 (15.4% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the FRA:36X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
68GF Score

Get the complete analysis for FRA:36X

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.80
Price
€4.49
GF Value